What is Fibronostics?
Headquartered across Singapore and New York, Fibronostics operates at the intersection of advanced data science and clinical medicine. The company specializes in algorithm-based diagnostic solutions, with a primary focus on the screening, progression, and prognosis of chronic conditions, particularly liver and kidney diseases. As a SPRIM portfolio company, Fibronostics benefits from a deep-rooted pedigree in worldwide health innovation and consulting. Its commercial reach spans North America, Asia, Europe, and LATAM, positioning it as a critical infrastructure provider for healthcare systems seeking to transition toward non-invasive, AI-driven diagnostic protocols. The firm's ability to scale these proprietary algorithms globally has made it a standout entity in the competitive diagnostics market.
How much funding has Fibronostics raised?
Fibronostics has raised a total of $14.5M across 2 funding rounds:
Series A
$8M
Unspecified
$6.5M
Series A (2020): $8M with participation from Elev8.vc and AT Capital
Unspecified (2022): $6.5M, investors not publicly disclosed
Key Investors in Fibronostics
AT Capital
AT Capital Group is a prominent family office that specializes in actively managed businesses and passive financial investments, focusing on sustainable growth across real estate, renewable energy, and private credit.
Elev8.vc
Elev8.vc is a venture capital firm that focuses on early-stage technology investments, providing the necessary capital and strategic guidance to help startups scale their operations effectively.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Fibronostics?
With the recent capital injection, Fibronostics is poised to deepen its penetration into key international markets while refining its AI-driven diagnostic suite. The strategic roadmap likely involves expanding the clinical utility of its liver and kidney disease screening tools, potentially targeting new chronic conditions to broaden its diagnostic portfolio. As the company matures beyond its Series A foundation, the focus will shift toward operational excellence and the integration of its technology into broader hospital information systems. Investors are closely monitoring the firm's ability to maintain its competitive edge in the rapidly evolving digital health sector, where regulatory compliance and clinical validation remain the primary barriers to entry and growth.
See full Fibronostics company page
